Abstract
Bone marrow fibrosis (MF) is a pathologic process with excessive cytokines stimulating bone marrow stromal fibroblasts to produce reticulin and collagen. MF is different from the independent disease called primary myelofibrosis (PMF). A fraction of patients with mild MF show rare teardrop poikilocytosis in peripheral blood and have an excellent prognosis after a short course of corticosteroid therapy. The clinicopathologic syndrome is described as autoimmune myelofibrosis (AIMF) because it′s constantly related with autoimmune diseases. AIMF probably represents the inflammatory state before MPN or it could be a distinct entity resulted from excessive fibrogenic cytokines produced by lymphocytes because of chronic inflammation and abnormal immunity in bone marrow stroma. This article focuses on the research progresses of pathogenesis, diagnosis and treatment of AIMF. Key words: Autoimmune myelofibrosis; Bone marrow fibrosis; Chronic inflammation; Cytokines; Pathogenesis; Diagnosis; Drug therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
